Alembic Pharma receives USFDA nod for Amlodipine and Atorvastatin Tablets
Amlodipine and Atorvastatin tablets are a combination medication used to treat high blood pressure (hypertension) and high cholesterol (hyperlipidemia).
The approved product is therapeutically equivalent to the reference listed drug, Caduet Tablets, marketed by Pharmacia and Upjohn Co. LLC.
The company now has a cumulative total of 223 ANDA approvals from the USFDA, including 199 final approvals and 24 tentative approvals.
Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company. It manufactures and markets generic pharmaceutical products all over the world. Its research and manufacturing facilities are approved by regulatory authorities of many developed countries, including the USFDA.
The companys consolidated net profit declined 12% to Rs 156.89 crore despite a 16.7% jump in net sales to Rs 1,769.64 crore in Q4 FY25 over Q4 FY24.
The counter shed 0.13% to Rs 971.25 on the BSE.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
12 minutes ago
- Economic Times
Indiqube Spaces IPO subscribed 2.8 times on final day of bidding, GMP at 5%. Should you subscribe?
On the final day of bidding, the initial public offering (IPO) of Indiqube Spaces was subscribed 2.8 times. Indiqube Spaces IPO: Retail investors demonstrated the strongest interest, with their portion oversubscribed 7.74 times. The Non-Institutional Investor (NII) segment saw a subscription of 2.26 times, while Qualified Institutional Buyers (QIBs) subscribed 1.42 times to their allotted quota. Tired of too many ads? Remove Ads Indiqube IPO details Tired of too many ads? Remove Ads Utilization of proceeds by Indiqube Here is what the brokerage firms say about the issue: Anand Rathi: At the upper price band company is valuing at P/S of 4.7x with EV/EBITDA of 14.6x and a market cap of Rs 49,771 million post issue of equity shares. The brokerage firm believes that the IPO is fully priced and recommends a 'Subscribe-Long term' rating to the IPO. At the upper price band company is valuing at P/S of 4.7x with EV/EBITDA of 14.6x and a market cap of Rs 49,771 million post issue of equity shares. The brokerage firm believes that the IPO is fully priced and recommends a 'Subscribe-Long term' rating to the IPO. Bajaj Broking: At the upper end of the IPO price band, the company is valued at 4x, 5x, and 7x its FY25, FY24, and FY23 sales, respectively—largely in line with its listed peer, Awfis Space, which trades at 4x, 5x, and 8x sales for the same periods. With this, they have a 'Subscribe for long term' rating on the IPO. At the upper end of the IPO price band, the company is valued at 4x, 5x, and 7x its FY25, FY24, and FY23 sales, respectively—largely in line with its listed peer, Awfis Space, which trades at 4x, 5x, and 8x sales for the same periods. With this, they have a 'Subscribe for long term' rating on the IPO. Lemonn Markets Desk: While IndiQube is loss-making, it is operating in a high-growth, underpenetrated sector with strong operational metrics and scalable tech-driven business. Its dominant presence in India's most active office markets, efficient capital model, and VAS ecosystem position it well to capitalize on the office space revival and GCC expansion. However, due to rich valuations and continued losses, the IPO is better suited for investors with a long-term horizon and moderate risk appetite. The brokerage firm has a 'Subscribe for long term' rating for the issue. About Indiqube Spaces The initial public offering (IPO) of Indiqube Spaces was subscribed 2.8 times so far on Friday, the final day of the bidding process. The IPO garnered bids for 4,80,83,112 shares against the 1.71 crore shares on investors showed the highest interest, with their portion subscribed 7.74 times. The Non-Institutional Investor (NII) segment was subscribed 2.26 times, while Qualified Institutional Buyers (QIBs) subscribed to their allocated quota by 1.42 the grey market, Indiqube Spaces shares were trading at a premium of Rs 12–Rs 13, indicating a potential listing gain of around 5.06% over the upper end of the IPO price band, down from 7% on IPO price band is set between Rs 225 and Rs 237 per share, with a lot size of 63 shares, requiring a minimum investment of Rs 14,931 at the upper total issue size stands at Rs 700 crore, comprising a fresh issue of Rs 650 crore, the proceeds of which will go to the company, and an offer for sale (OFS) of Rs 50 crore by existing Securities is acting as the lead manager for the issue, and MUFG Intime India is the plans to deploy Rs 462.65 crore from the fresh issue proceeds to set up new workspaces. An additional Rs 93 crore will be used to repay or prepay borrowings, with the balance allocated for general corporate in 2015 as Innovent Spaces Pvt. Ltd., Indiqube Spaces provides modern and sustainable office solutions. Originally based in Uttar Pradesh, the company shifted its headquarters to Bengaluru in FY25, the company posted a revenue of Rs 1,102.93 crore, marking a 27% increase from Rs 867.66 crore in FY24. The net loss narrowed significantly to Rs 139.62 crore in FY25, compared to Rs 341.51 crore in the previous year.: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
News18
12 minutes ago
- News18
Noida: 2.6km Metro Extension To Bodaki Gets Central Green Signal, Know More
Noida: 2.6km Metro Extension To Bodaki Gets Central Green Signal, Know More Curated By : Last Updated: July 25, 2025, 12:09 IST The new stretch will improve connectivity in deeper parts of Greater Noida, including Junpat village. Advertisement The central government has officially cleared a 2.6-kilometre extension of Noida Metro's Aqua Line from Depot station to Bodaki in Greater Noida. This stretch will be built on standard gauge (1,435mm) with a 15kV AC overhead wire system. (Photo: Swarajya) This crucial link will connect passengers to the proposed multi-modal logistics hub and promises to be ready in three years. The total cost of the project is Rs 416.34 crore, as per Hindustan Times. Recommended Stories Why Does This Matter? This small extension is set to make a big impact. It will take metro access deeper into Greater Noida, reaching areas like Bodaki and Junpat village. With growing residential and industrial developments in these regions, the improved connectivity is expected to boost travel ease and reduce reliance on road transport. Who's Funding the Project? The financial load will be shared among various government agencies. Rs 211.80 crore will come from central institutions like the National Capital Region Planning Board. The Centre will pitch in with Rs 70.59 crore. Uttar Pradesh government will contribute Rs 91.08 crore. Rs 10.44 crore will go towards land acquisition. What's Next on the Cards? While the Bodaki extension is a go, NMRC is now eyeing the green light for two more projects: A major 11.56km link from Botanical Garden to Noida Sector 142 A 5km connection from Sector 51 to Knowledge Park 5 in Greater Noida West top videos View all Swipe Left For Next Video View all The Botanical Garden route is especially crucial, as it will bring seamless integration between Delhi Metro's Blue Line and Noida Metro's Aqua Line, making it easier to reach Noida International Airport in Jewar. NMRC has already completed the topography survey for the 11.56km route, mapping buildings, homes, and markets along the planned track. Once approved, work will begin at full speed. About the Author Samreen Pall Samreen Pall, Senior Sub-Editor at News18, is a Computer Science graduate but a writer at heart, Samreen has one motto that she swears by: 'Everything is dull and useless if it has no drama in it.' This motto c... Read More Samreen Pall, Senior Sub-Editor at News18, is a Computer Science graduate but a writer at heart, Samreen has one motto that she swears by: 'Everything is dull and useless if it has no drama in it.' This motto c... Read More Get the latest updates on car and bike launches in India — including reviews, prices, specs, and performance. Stay informed with breaking auto industry news , EV policies, and more, Also Download the News18 App to stay updated! view comments First Published: July 25, 2025, 12:09 IST News auto Noida: 2.6km Metro Extension To Bodaki Gets Central Green Signal, Know More
Time of India
12 minutes ago
- Time of India
SOM Distilleries forays into mid-premium whisky segment with Mahavat
New Delhi: SOM Group of Companies has entered the mid-premium whisky segment with the launch of Mahavat, priced in the Rs 1000–1100 range, the company said in a press release on Friday. The company, known for its presence in value and mass-market categories, is looking to tap into rising demand for premium offerings in the regular whisky category. The launch begins with select outlets in Bhopal, followed by a phased rollout across Madhya Pradesh. Expansion into Delhi NCR and other key markets is expected to follow. 'The process began with deep exploration into consumer palates across India - from seasoned whisky connoisseurs to emerging enthusiasts - uncovering preferences for richness, smoothness, and a signature finish that lingers like legacy itself,' said Deepak Arora, CEO, SOM Group of Companies. The move marks a shift in SOM's strategy as it looks to build a presence in India's expanding premium alcobev market .
